宏源药业：罗田六氟磷酸钠项目部分已达预定可使用状态，公司将其由在建工程转入固定资产核算

Group 1 - The core issue raised by investors pertains to the significant difference between the beginning and ending balances of the construction in progress for the Luotian hexafluorophosphate sodium project in the 2025 semi-annual report [2] - The company clarified that the decrease in the balance is primarily due to part of the project reaching the intended usable state, leading to its reclassification from construction in progress to fixed assets in accordance with the Accounting Standards for Enterprises [2]